Cover Image
市場調查報告書

Rytary/IPX066(帕金森氏症)- 預測與市場分析

Rytary/IPX066 (Parkinson's Disease) - Forecast and Market analysis to 2022

出版商 GlobalData 商品編碼 301436
出版日期 內容資訊 英文 88 Pages
訂單完成後即時交付
價格
Back to Top
Rytary/IPX066(帕金森氏症)- 預測與市場分析 Rytary/IPX066 (Parkinson's Disease) - Forecast and Market analysis to 2022
出版日期: 2014年03月31日 內容資訊: 英文 88 Pages
簡介

帕金森氏症的症狀是以動作緩慢、肌肉僵硬、震顫和姿勢不穩為特徵的一個漸進式疾病。是發病率第二高的神經退化性疾病,無論何種年齡層都有受到影響的可能性,得病率隨著年齡增長而上升,高齡者更是常見。雖然多巴胺療法對動作遲緩相當有效,但仍留有許多未滿足需求。

本報告提供帕金森氏症治療藥物──Rytary/IPX066之調查分析,提供疾病概要和治療指南,競爭情形,產品資訊,主要國家的銷售額預測等,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
    • 預測
    • QOL
  • 症狀

第4章 疾病的管理

  • 概要
  • 治療概要
  • 帕金森氏症的評估規模

第5章 競爭評估

  • 概要
  • 策略性競爭企業的評估

第6章 機會及未滿足需求

  • 概要
  • 運動併發症的治療
  • 非運動併發症的治療
  • 神經保護/疾病修飾劑
  • 改善藥物配方
  • 可靠性高的生物標記
  • 改善臨床試驗的設計

第7章 開發平台評估

  • 概要
  • 臨床開發中的潛力藥物

第8章 Rytary/IPX066

  • 概要
  • 功效
  • 安全性
  • 給藥·處方
  • 潛在的臨床性地位
  • 潛在的商業性地位
  • 價格與回本
  • SWOT分析
  • 預測

第9章 附錄

圖表

目錄
Product Code: GDHC401DFR

Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson's disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

Rytary, also known as IPX066, is a levodopa-based product for the treatment of early and advanced Parkinson's disease. It was developed by the generics manufacturer Impax Laboratories and contains a capsule with different-sized beads that dissolve at different rates, releasing a 1:4 ratio of carbidopa: levodopa.

Scope

  • Overview of Parkinson's disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Rytary including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Rytary for the top six countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain and the UK.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Parkinson's disease
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Rytary performance
  • Obtain sales forecast for Rytary from 2012-2022 in the top six countries (the US, France, Germany, Italy, Spain and the UK).

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Overview
    • 4.1.1. Diagnosis - The UK Brain Bank Criteria
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
  • 4.2. Treatment Synopsis
    • 4.2.1. Dopaminergic Therapy Classes
    • 4.2.2. Treatment of Parkinson's Disease by Stage
    • 4.2.3. Other Treatment Options
  • 4.3. Parkinson's Disease Assessment Scales
    • 4.3.1. Unified Parkinson's Disease Rating Scale (UPDRS)
    • 4.3.2. Hoehn and Yahr Clinical Staging
    • 4.3.3. Other Clinical Assessments

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Treatment of Motor Complications - Dyskinesias and OFF Episodes
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Treatment of Non-Motor Symptoms and Dementia
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Neuroprotective/Disease-Modifying Agents
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Improved Drug Formulations
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Identification of Reliable Biomarkers
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Improved Clinical Trial Design
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development

8. Rytary/IPX066

  • 8.1. Overview
  • 8.2. Efficacy
  • 8.3. Safety
  • 8.4. Dosing and Formulation
  • 8.5. Potential Clinical Positioning
  • 8.6. Potential Commercial Positioning
  • 8.7. Pricing and Reimbursement
  • 8.8. SWOT Analysis
  • 8.9. Forecast

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Parkinson's Disease Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. General Pricing Assumptions
    • 9.4.4. Compliance Assumptions
    • 9.4.5. Individual Drug Assumptions
    • 9.4.6. Generic Erosion
    • 9.4.7. Pricing of Pipeline Agent
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. About the Authors
    • 9.6.1. Author
    • 9.6.2. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Parkinson's Disease
  • Table 2: UK Brain Bank Diagnostic Criteria
  • Table 3: Diagnosis and Treatment Guidelines for Parkinson's Disease
  • Table 4: Most Prescribed Drugs for Parkinson's Disease by Class in the Global Markets, 2014
  • Table 5: Dopaminergic Therapy in Parkinson's Disease
  • Table 6: UPDRS Clinical Assessment of Disease Severity
  • Table 7: Parkinson's Disease Assessment Scales Used in Clinical Trials
  • Table 8: Treatment of Motor Symptoms in Parkinson's Disease
  • Table 9: Leading Treatments for Parkinson's Disease, 2014
  • Table 10: Unmet Need and Opportunity in Parkinson's Disease
  • Table 11: Dyskinesia Pipeline, 2014
  • Table 12: Dementia Pipeline, 2014
  • Table 13: Parkinson's Disease-Modifying Therapeutics Pipeline, 2014
  • Table 14: Product Profile - Rytary
  • Table 15: Rytary SWOT Analysis, 2014
  • Table 16: Global Sales Forecasts ($m) for Rytary, 2012-2022

List of Figures

  • Figure 1: Overview - L-dopa Metabolism and Inhibitor Classes
  • Figure 2: Overview - Treatment of Motor Symptoms of Parkinson's Disease
  • Figure 3: Pharmacokinetics of Levodopa
  • Figure 4: Parkinson's Disease - Phase II-III Pipeline, Segmented by Indication, 2014
  • Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in Parkinson's Disease, 2012-2022
Back to Top